Additional InformationTHE PHARMACEUTICAL MARKET: ARGENTINA - REVIEW
The Argentine pharmaceutical market will be the third most attractive in Latin America and the fifth in the Americas region in 2016. It is often compared in size to Venezuela, but they are very different markets. Espicom projects a double-digit CAGR in local terms but a high single-digit CAGR in US dollar terms between 2011 and 2016. Pharmaceutical consumption will continue to rise but is not expected to show the exceptional growth rate in US dollar terms registered in recent years, as the economy fell in US dollar terms in 2009 and the peso is expected to weaken against the dollar over the period. In May 2011, ANMAT announced the implementation of the pharmaceutical traceability system, in order to control drug safety and help to eradicate drug counterfeiting in the country. Resolution No. 435/2011 regulates the new system.
Including internal demand, exports and imports, pharmaceutical sales at manufacturers’ prices rose by 28.4% in local terms and 21.0% in US dollar terms in QII 2011. The central nervous system represented 15.9% of the total, followed by the cardiovascular system (15.7%) and the alimentary tract & metabolism (13.7%). Sales from Argentine producers represented 29.0% of the total, followed by Indian producers (15.6%) and German producers (7.6%). Pharmaceutical production at manufacturers’ prices rose by 30.3% in local terms and 22.9% in US dollar terms in QII 2011, most of which was accountable to internal demand. In June 2011, the Senate approved a law to regulate the public production of medicaments, vaccines and medical products in the country. This is expected to strengthen the public sector in the country.
There are over 200 pharmaceutical companies operating in the pharmacy sector, of which over half are Argentine. Local producers dominate the pharmacy sector, led by Roemmers, Bagó, Gador and Elea. Recent significant developments include the agreement to start the construction of the Polo Farmacéutico de Buenos Aires, signed by 13 local companies in October 2011; Roemmers’ acquisition of 50.0% of a small local OTC company, reported in July 2011; and Roemmers’ two-year agreement to distribute and sell 26 primary care products from a Swiss company, announced in January 2011. Mexico and Brazil offer more incentives for multinationals to set up their regional subsidiaries, but two foreign companies made recent strategic acquisitions in the Argentine oncology market in QIII 2011.
ENHANCED STRATEGIC INTELLIGENCE
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.